

severe lipid storage phenotype of Wolman disease fibroblasts. Electron microscopy confirmed significant correction of the lysosomal lipid storage in AdhLAL-infected Wolman disease fibroblasts at the ultrastructural level. I.v. injection of AdhLAL into wild-type mice resulted in a 13.5-fold increase in hepatic LAL activity, and overexpression of LAL was not associated with toxic side effects. These data demonstrate high-level lysosomal expression of recombinant LAL in vitro and in vivo and show the feasibility of gene therapeutic strategies for the treatment of Wolman disease.

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D His

(FILE 'HOME' ENTERED AT 10:55:57 ON 22 FEB 2007)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 10:56:40 ON  
22 FEB 2007

E GRABOWSKI GREGORY/AU  
L1 257 S E2, E3, E4  
E DU HONG/AU  
L2 229 S E3  
L3 453 S L1 OR L2  
L4 2158 S ("LIPID HYDROLYING PROTEIN" OR "LIPID HYDROLASE" OR "LYSOSOMA  
L5 46 S L3 AND L4  
L6 2563 S "GENE THERAPY" AND "VIRAL VECTOR" AND PLASMID  
L7 0 S L4 AND L6  
L8 12605 S "GENE THERAPY" AND "VIRAL VECTOR"  
L9 2563 S L6 AND L8  
L10 0 S L4 AND L8  
L11 23 S L4 AND "GENE THERAPY"  
L12 63 S L5 OR L11  
L13 9 S L12 AND VECTOR  
L14 1 S L12 AND PLASMID  
L15 1 S L14 AND (LIPOSOME OR "LIPID VESICLE")  
L16 0 S L12 AND "VIRAL VECTOR"  
L17 9 S L13 OR L14 OR L15  
L18 5 DUP REM L17 (4 DUPLICATES REMOVED)  
L19 30 DUP REM L12 (33 DUPLICATES REMOVED)

=> Logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
165.19	165.40

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-15.60	-15.60

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 11:12:27 ON 22 FEB 2007